Please assess the completion status of the following clinical trial:

Trial Title: Effects of Botox in Obstructed Defecation Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years or older of all races and backgrounds~* Competent to give informed consent~* Meet the Rome III diagnostic criteria for functional constipation~* Inability to relax the puborectalis muscle at electromyography~* Altomare Obstructed Defecation Syndrome score of 15 points or above~* Failure of treatment with 2 conservative measures which may be as follows:~  * 1 laxative (osmotic or stimulant) for 2 weeks~ * 1 fiber supplement for one month~ * And/or trial of biofeedback for at least 4 sessions~Exclusion Criteria:~* Previous treatment with Botox (possible antibodies)~* Known hypersensitivity to any of the components of the toxin~* Medication regimen includes narcotics~* Previous radiation therapy to the anal canal and rectum~* Prior proctectomy~* Presence of unhealed and symptomatic anal fissure~* Presence of anal pain~* Presence of fecal incontinence~* Presence of full thickness rectal prolapse~* Presence of internal sphincter myopathy~* Inflammatory bowel disease or proctitis~* Pregnancy or breast-feeding~* Subject is currently enrolled/ just finished participating in a clinical trial in which the intervention/ its carry-over effect may interact with the intervention in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum Toxin-A (Type: ACTIVE_COMPARATOR): Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
- Normal saline (Type: PLACEBO_COMPARATOR): Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.

Based on this trial design, predict the completion outcome and termination type (if applicable).